Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1986 Sep;39(9):977–980. doi: 10.1136/jcp.39.9.977

Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

J Gerdes, R J Lelle, H Pickartz, W Heidenreich, R Schwarting, L Kurtsiefer, G Stauch, H Stein
PMCID: PMC500196  PMID: 3020096

Abstract

The growth fractions of 160 mammary carcinomas and 30 benign mammary lesions were determined in situ by immunostaining with the monoclonal antibody Ki-67. Benign lesions had a mean value of 3% Ki-67 positive cells, whereas the mean value of mammary carcinomas was 16.6%. A comparison of the mean values of Ki-67 positive cells with the histological grade of the tumours showed a correlation between these two variables--that is, histological grade 1 showed 9%, grade 2 16%, and grade 3 26% proliferating cells. Considering the individual Ki-67 values in the different histological grades, it was evident that there was considerable scatter in the number of proliferating cells, so that the proliferation rates of grades 1, 2, and 3 overlapped each other. This indicates a dissociation between histological grade of malignancy and size of the growth fraction in most breast cancers. Follow up studies are needed to establish which of the two variables--that is, morphological degree of malignancy, or the proportion of Ki-67 positive cells--correlates better with response to treatment and survival in individual cases.

Full text

PDF
980

Images in this article

978Image
on p.978
978Image
on p.978

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Charlson M. E., Feinstein A. R. Rapid growth rate in breast cancer: a confounding variable in adjuvant-chemotherapy trials. Lancet. 1982 Jun 12;1(8285):1343–1345. doi: 10.1016/s0140-6736(82)92410-2. [DOI] [PubMed] [Google Scholar]
  3. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  4. Cutler S. J., Black M. M., Friedell G. H., Vidone R. A., Goldenberg I. S. Prognostic factors in cancer of the female breast. II. Reproducibility of histopathologic classification. Cancer. 1966 Jan;19(1):75–82. doi: 10.1002/1097-0142(196601)19:1<75::aid-cncr2820190108>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  5. Gerdes J., Dallenbach F., Lennert K., Lemke H., Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol. 1984 Oct-Dec;2(4):365–371. doi: 10.1002/hon.2900020406. [DOI] [PubMed] [Google Scholar]
  6. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  7. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  8. Haag D., Goerttler K., Tschahargane C. The proliferative index (PI) of human breast cancer as obtained by flow cytometry. Pathol Res Pract. 1984 Mar;178(4):315–322. doi: 10.1016/S0344-0338(84)80020-5. [DOI] [PubMed] [Google Scholar]
  9. Meyer J. S., Friedman E., McCrate M. M., Bauer W. C. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983 May 15;51(10):1879–1886. doi: 10.1002/1097-0142(19830515)51:10<1879::aid-cncr2820511021>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  10. Meyer J. S., Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res. 1979 Oct;39(10):4042–4047. [PubMed] [Google Scholar]
  11. Meyer J. S., Lee J. Y. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed] [Google Scholar]
  12. Stein H., Gerdes J., Schwab U., Lemke H., Mason D. Y., Ziegler A., Schienle W., Diehl V. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982 Oct 15;30(4):445–459. doi: 10.1002/ijc.2910300411. [DOI] [PubMed] [Google Scholar]
  13. Stenkvist B., Westman-Naeser S., Vegelius J., Holmquist J., Nordin B., Bengtsson E., Eriksson O. Analysis of reproducibility of subjective grading systems for breast carcinoma. J Clin Pathol. 1979 Oct;32(10):979–985. doi: 10.1136/jcp.32.10.979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tubiana M., Pejovic M. J., Renaud A., Contesso G., Chavaudra N., Gioanni J., Malaise E. P. Kinetic parameters and the course of the disease in breast cancer. Cancer. 1981 Mar 1;47(5):937–943. doi: 10.1002/1097-0142(19810301)47:5<937::aid-cncr2820470520>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  15. Valeriote F., van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975 Oct;35(10):2619–2630. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES